Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

Gallup reports 11% of U.S. adults are currently using GLP-1s for weight loss (vs. 3% in 2024), a major demand tailwind for Eli Lilly and Novo Nordisk. Eli Lilly posted Q1 tirzepatide sales of $8.7B for Mounjaro and $4.2B for Zepbound for combined $12.9B, lifting total Q1 revenue to $19.8B (+56% YoY). Management raised full-year 2026 revenue guidance to $82.2B–$85B (up $2B from prior), and Lilly’s newly approved oral GLP-1 “Foundayo” is expected to further accelerate weight-loss sales; shares are up ~14% YTD and ~6% over the past month.

Analysis

The real incremental signal here is not that GLP-1 demand is strong; it is that the category is still in the first inning of payer normalization. Once awareness and trial rates cross a certain threshold, the bottleneck shifts from consumer education to reimbursement design and manufacturing throughput, which tends to favor the best-capitalized incumbent with the cleanest supply chain. That is structurally supportive for LLY versus smaller obesity entrants, but it also means the next leg of upside depends on execution, not just market growth.

Near term, the biggest second-order effect is competitive friction inside the class. An oral option reduces injection aversion and widens the addressable pool, but it also raises the probability of steeper employer utilization management and more aggressive step-therapy by PBMs over the next 1-3 quarters. That caps the speed at which the category can re-rate, especially for a stock already pricing in near-perfect continuation.

The contrarian point is that the market may be underestimating how much of this demand is already embedded in consensus. At this valuation, LLY needs repeated guide raises and no evidence of margin dilution from capacity build or rebates; otherwise the multiple can compress even if unit demand stays healthy. For NVO, the setup is more mixed: competitive pressure is real, but the bar is lower and any perception that oral adoption is broadening the market could support a relief rally if share loss stabilizes.

Over 6-18 months, watch for insurer pushback, gross margin trajectory, and whether the oral format is additive or cannibalistic to higher-priced injectables. If the class remains supply-constrained, the winners are the companies that can convert demand into shipped volume fastest; if supply normalizes, price competition and rebate intensity become the main margin risk.

Key Decisions for Investors

• Do not chase LLY after strength; wait for a 5-7% pullback before adding. Use 2026 consensus revenue and gross margin as the gate: if either stops improving, the multiple is vulnerable to 10-15% compression over 1-3 months.
• Relative-value: long LLY / short NVO over 3-6 months if you want exposure to GLP-1 adoption with the cleaner execution story. Thesis fails if NVO shows share stabilization or if LLY’s supply/margin profile worsens.
• For existing LLY holders, hedge into the next earnings print with a put spread or covered-call overlay. The trade is about de-risking valuation, not fighting the underlying demand trend.
• Set an alert on payer commentary and utilization management language across major PBMs over the next 1-2 quarters. A move toward stricter prior auth would be the clearest signal to trim exposure to the whole obesity basket.